Avadel Pharmaceuticals (AVDL)

The consensus price target hints at a 37.3% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Th...

GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceutic...

ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since i...

ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug, t...

ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.

The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positiv...

Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).